Aoxiang Pharmaceutical announced on November 2. Recently, SpiRig HealthCare AG, a subsidiary of the company's partner StadaArzneimittel AG, received a marketing license for rucotinib tablets approved and issued by the Swiss Medicines Administration. This formulation product is one of the products jointly developed and commercialized by the company and STADA. The company undertakes the production task of this formulation product, while the sales work is carried out separately by both parties in their respective responsible market regions.

Zhitongcaijing · 11/02 07:41
Aoxiang Pharmaceutical announced on November 2. Recently, SpiRig HealthCare AG, a subsidiary of the company's partner StadaArzneimittel AG, received a marketing license for rucotinib tablets approved and issued by the Swiss Medicines Administration. This formulation product is one of the products jointly developed and commercialized by the company and STADA. The company undertakes the production task of this formulation product, while the sales work is carried out separately by both parties in their respective responsible market regions.